Neurimmune Therapeutics
20 articles with Neurimmune Therapeutics
-
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases
1/17/2022
Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.
-
Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006
1/7/2022
Neurimmune AG announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca's Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.
-
On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.
-
FDA Approval of Aducanumab
6/7/2021
Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen's regulatory application for the use of aducanumab in the treatment of Alzheimer's disease
-
BioSpace Global Roundup, April 2
4/2/2020
Biopharma companies from across the globe provide updates on their pipelines and business practices. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19
4/1/2020
Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19.
-
Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy
2/27/2020
Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy).
-
Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab
10/22/2019
Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies.
-
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
10/16/2019
AL-S Pharma AG and TVM Capital Life Science, announced enrollment of the first patient in a multicenter Phase 1 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis AP-101 is a human antibody directed against misfolded superoxide dismutase 1 The antibody has been discovered by translating genetic information of human memory B cells through Neurimmune's Reverse Translational Medicine™ technology.
-
BioSpace Movers and Shakers: March 8
3/8/2019
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family. -
Cambridge, Mass.-based Biogen and Tokyo, Japan-based Eisai Co. announced results from an analysis of their ongoing long-term extension (LTE) Phase Ib trial of aducanumab for Alzheimer’s disease.
-
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
5/1/2018
Transaction increases profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune.
-
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
11/9/2017
Under the deal, Neurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine technology platform.
-
Despite the failures of late stage ALZ's drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.
-
Neurimmune Therapeutics And TVM Capital Life Science Announce Creation Of AL-S Pharma To Develop Innovative Therapy For Patients With ALS
12/7/2016
-
Neurimmune Therapeutics Release: Early Results Show Aducanumab Removes Amyloid Plaques In Patients With Alzheimer’s Disease
8/31/2016
-
Neurimmune Therapeutics Receives Major Development Milestone Upon Initiation Of Global Phase 3 Studies With Aducanumab For Early Alzheimer's Disease
9/8/2015
-
Biogen Idec, Inc. (Massachusetts) Picks Up Neurimmune Therapeutics's Neurogenerative Programs for $32.5M Upfront With Potential for $395 Million More
12/21/2010
-
Neurimmune Therapeutics Awarded the 2010 ZKB TECHNOPARK(R) Pioneer Award
4/14/2010